Effectiveness of a new tobramycin (0.3 % ) and dexamethasone (0.05 % ) formulation in the treatment of experimental Pseudomonas keratitis

References

• Notivol R, Amin D, Whitling A, . Prophylactic effectiveness of tobramycin-dexamethasone eye drops compared with tobramycin/vehicle eye drops in controlling post-surgical inflammation in cataract patients: prospective, randomized, double-masked, two-arm, parallel group, placebo-controlled, multicentre study. Clin Drug Investig 2004;24: 523–33
   PubMed Web of Science ®Google Scholar
• Notivol R, Bertin D, Amin D, . Comparison of topical tobramycin-dexamethasone with dexamethasone-neomycin-polymyxin and neomycin-polymyxin-gramacidin for control of inflammation after cataract surgery: results of a multicenter, prospective, three-arm, randomized, double-masked, controlled parallel-group study. Clin Ther 2004;26: 1274–85
   PubMed Web of Science ®Google Scholar
• Camesasca FI, Bianchi C, Beltrame G, . Control of inflammation and prophylaxis of endophthalmitis after cataract surgery: a multicenter study. Eur J Ophthalmol 2007;17: 733–42
   PubMed Web of Science ®Google Scholar
• Russo S, Papa V, Di Bella A, . Dexamethasone-netilmicin: a new ophthalmic steroid-antibiotic combination. Efficacy and safety after cataract surgery. Eye 2007;21: 58–64
   PubMed Web of Science ®Google Scholar
• Rhee SS, Mah FS. Comparison of tobramycin 0.3 % / dexamethasone 0.1 % and tobramycin 0.3 % /loteprednol 0.5 % in the management of blepharo-keratoconjunctivitis. Adv Ther 2007;24: 60–7
   PubMed Web of Science ®Google Scholar
• White EM, Macy JI, Bateman KM, Comstock TL. Comparison of the safety and efficacy of loteprednol 0.5 % /tobramycin 0.3 % with dexamethasone 0.1 % /tobramycin 0.3 % in the treatment of blepharokeratoconjunctivitis. Curr Med Res Opin 2008;24: 287–96
   PubMed Web of Science ®Google Scholar
• Meseguer G, Buri P, Plazonnet B, . Gamma scintigraphic comparison of eye drops containing pilocarpine in healthy volunteers. J Ocul Pharmacol Ther 1996;12: 481–8
   PubMed Web of Science ®Google Scholar
• Albasini M, Ludwig A. Evaluation of polysaccharides intended for ophthalmic use in ocular dosage forms. Farmaco 1995;50: 633–42
   PubMedGoogle Scholar
• Ceulemans J, Vinckier I, Ludwig A. The use of xanthan gum in an ophthalmic liquid dosage form: rheological characterization of the interaction with mucin. J Pharm Sci 2002;91: 1117–27
   PubMed Web of Science ®Google Scholar
• Scoper SV, Kabat AG, Owen GR, . Ocular distribution, bactericidal activity, and settling characteristics of TobraDex® ST compared with TobraDex® ophthalmic suspension. Adv Ther29 February20082008 published online, doi: 10.1007/s12325-008-0019-9
   Web of Science ®Google Scholar
• Umamaheswara Reddy C, Arun A, . Polymeric drug based on sulfanilamide: synthesis, antimicrobial and drug releasing studies. J Pharm Pharmacol 2007;59: 1207–13
   PubMed Web of Science ®Google Scholar
• Grare M, Mourer M, Fontanay S, . In vitro activity of para-guanidinoethylcalix[4]arene against susceptible and antibiotic-resistant gram-negative and gram-positive bacteria. J Antimicrob Chemother 2007;60: 575–81
   PubMed Web of Science ®Google Scholar
• Hobden JA, Hill JM, Engel LS, O'Callaghan RJ. Age and therapeutic outcome of experimental Pseudomonas aeruginosa keratitis treated with ciprofloxacin, prednisolone, and flurbiprofen. Antimicrob Agents Chemother 1993;37: 1856–9
   PubMed Web of Science ®Google Scholar
• Guzek JP, Chacko D, Kettering JD, . Comparison of topical ciprofloxacin to conventional antibiotic therapy in the treatment of experimental Pseudomonas aeruginosa keratitis. Cornea 1994;13: 500–4
   PubMed Web of Science ®Google Scholar
• O'Callaghan RJ, Engel LS, Hobden JA, . Pseudomonas keratitis. The role of an uncharacterized exoprotein, protease IV, in corneal virulence. Invest Ophthalmol Vis Sci 1996;37: 534–43
   PubMed Web of Science ®Google Scholar
• O'Callaghan RJ, McCormick CC, Caballero AR, . Age-related differences in rabbits during experimental Staphylococcus aureus keratitis. Invest Ophthalmol Vis Sci 2007;48: 5125–31
   PubMed Web of Science ®Google Scholar
• Dajcs JJ, Thibodeaux BA, Girgis DO, O'Callaghan RJ. Corneal virulence of Staphylococcus aureus in an experimental model of keratitis. DNA Cell Biol 2002;21: 375–82
   PubMed Web of Science ®Google Scholar
• Engel LS, Callegan MC, Hobden JA, . Effectiveness of specific antibiotic/steroid combinations for therapy of experimental Pseudomonas aeruginosa keratitis. Curr Eye Res 1995;14: 229–34
   PubMed Web of Science ®Google Scholar
• Engel LS, Hobden JA, Moreau JM, . Pseudomonas deficient in protease IV has significantly reduced corneal virulence. Invest Ophthalmol Vis Sci 1997;38: 1535–42
   PubMed Web of Science ®Google Scholar
• Andrean SD, Cochrane R, Reilly CD, Mannis MJ. Infectious keratitis after astigmatic keratotomy in penetrating keratoplasty: review of three cases. Cornea 2005;24: 626–8
   PubMed Web of Science ®Google Scholar
• Constantinou M, Daniell M, Snibson GR, . Clinical efficacy of moxifloxacin in the treatment of bacterial keratitis: a randomized clinical trial. Ophthalmology 2007;114: 1622–9
   PubMed Web of Science ®Google Scholar
• Leibowitz HM, Kupferman A, Stewart RH, Kimbrough RL. Evaluation of dexamethasone acetate as a topical ophthalmic formulation. Am J Ophthalmol 1978;86: 418–23
   PubMed Web of Science ®Google Scholar
• Hobden JA, Engel LS, Hill JM, . Prednisolone acetate or prednisolone phosphate concurrently administered with ciprofloxacin for the therapy of experimental Pseudomonas aeruginosa keratitis. Curr Eye Res 1993;12: 469–73
   PubMed Web of Science ®Google Scholar
• Pavesio CE, Decory HH. Treatment of ocular inflammatory conditions with loteprednol etabonate. Br J Ophthalmol 2008doi:10.1136/bjo.2007.132621
   Web of Science ®Google Scholar
• McGhee CN, Dean S, Danesh–Meyer H. Locally administered ocular corticosteroids: benefits and risks. Drug Saf 2002;25: 33–55
   PubMed Web of Science ®Google Scholar
• Clark AF, Wilson K, de Kater AW, . Dexamethasone-induced ocular hypertension in perfusion-cultured human eyes. Invest Ophthalmol Vis Sci 1995;36: 478–89
   PubMed Web of Science ®Google Scholar
• Leibowitz HM, Kupferman A. Topically administered corticosteroids: effects on antibiotic treated bacterial keratitis. Arch Ophthalmol 1980;98: 1287–90
   PubMed Web of Science ®Google Scholar
• Davis SD, Sarff LD, Hyndiuk RA. Corticosteroid in experimentally induced Pseudomonas keratitis: failure of prednisolone to impair the efficacy of tobramycin and carbenicillin therapy. Arch Ophthalmol 1978;96: 126–8
   PubMed Web of Science ®Google Scholar